Clinical trials: Vascular Patients
Hypertension, Blood Pressure, High
Registry to Evaluate the ROX COUPLER in Patients With Resistant or Uncontrolled Hypertension
The purpose of this registry is to evaluate the safety and performance of the ROX COUPLER in patients with treatment-resistant or uncontrolled hypertension.
- Conditions
- Hypertension, Blood Pressure, High, Blood Pressure, Resistant, Blood Pressure, Uncontrolled
- Trial name
- NCT01885390
- Testing
- ROX COUPLER
- Where
- 4 sites in Belgium, Netherlands and 1 more
- Volunteers
- 83 people
- Sponsor
- ROX Medical, Inc.
HYPERTENSION
Hypertension and Cardiovascular Risk Factors
A study to evaluate the efficacy of valsartan+chydochlorothiazide in patients with stage 2 hypertension and cardiovascular risk factors.
- Trial name
- NCT00171782
- Testing
- VALSARTAN+HYDROCHLOROTHIAZIDE
- Volunteers
- 76 people
- Sponsor
- Novartis
Venous Thromboembolism
Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism
The study objective is to evaluate the efficacy and safety of oral YM150 for 52 weeks in patients with a history of venous thromboembolism.
- Trial name
- NCT00937820
- Testing
- YM150
- Where
- 5 sites in Japan
- Volunteers
- 87 people
- Sponsor
- Astellas Pharma Inc
Chronic Kidney Failure, Vascular Graft Occlusion
A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis
The study will look at the safety profile (unwanted effects) of the long-lasting anticoagulant PEG-hirudin (SPP200) and compare these unwanted effects to those of unfractionated heparin, commonly used in haemodialysis to avoid…
- Trial name
- NCT00074620
- Testing
- PEG-hirudin
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Speedel Pharma Ltd.
Multiple Myeloma, Plasma Cell Leukemia
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
This is a Phase 1 study during which patients with relapsed or refractory multiple myeloma (MM) or plasma cell leukemia (PCL) will receive investigational study drug ARRY-520 and bortezomib, with or without dexamethasone, with…
- Trial name
- NCT01248923
- Testing
- ARRY-520, KSP(Eg5) inhibitor; intravenous, Bortezomib, proteasome inhibitor; intravenous or subcutaneous, Dexamethasone, steroid; oral
- Where
- 13 sites in United States
- Volunteers
- 55 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Hypertension (HTN)
A Phase Ⅰ b Clinical Study of ART101 Injection
This is an open-label, single dose Phase Ib clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of a single subcutaneous injection of ART101 in patients with…
- Trial name
- NCT07614308
- Testing
- ART101 injection
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Arnatar Therapeutics, Inc.
Stroke, Atrial Fibrillation
Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation
This study is to demonstrate the safety and efficacy profile, in two different dose regimens of Edoxaban (DU-176b), (an investigational new drug being tested for the prevention of stroke/systemic embolic events (SEE)), in…
- Conditions
- Stroke, Atrial Fibrillation, Embolism
- Trial name
- EngageAFTIMI48 (NCT00781391)
- Testing
- warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg)
- Where
- 1,009 sites in United States, Argentina and 44 more
- Volunteers
- 21,105 people
- Sponsor
- Daiichi Sankyo
Multiple Myeloma
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
This Phase 1 study of oral CX-4945 is designed to test the safety, tolerability, and highest safe dose level of this CK2 inhibitor in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01199718
- Testing
- CX-4945
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Cylene Pharmaceuticals
Intermittent Claudication, Peripheral Artery Disease
A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication
The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with peripheral artery disease and…
- Trial name
- NCT01131013
- Testing
- 375 mg CK-2017357, 500 mg CK-2017357
- Where
- 14 sites in United States
- Volunteers
- 61 people
- Sponsor
- Cytokinetics
Ischemic Attack, Transient
Cognitive and Physical Functions in Patients With Transient Ischemic Attack. A Randomized Controlled Trial of Physical Activity on Prescription up to One Year After the Event
The purpose of this study is to determine whether Physical Activation on Prescription can help patients with TIA to become more physically active.
- Trial name
- NCT01509924
- Testing
- Physical activation on Prescription
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Tiohundra AB
Hypertension
A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients
The purpose of this study is to evaluate the effects of various doses of nebivolol in patients with mild to moderate hypertension.
- Trial name
- NCT00200460
- Testing
- Nebivolol
- Where
- United States
- Volunteers
- 825 people
- Sponsor
- Mylan Bertek Pharmaceuticals
Macular Degeneration
Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.
In this clinical study researchers want to gain a deeper understanding of treatment consistence under real world conditions over the course of 24 months of Aflibercept injections into the eye for patients suffering from abnormal…
- Trial name
- ANDROMEDA (NCT03714308)
- Testing
- Ivt. Aflibercept (Eylea, BAY86-5321)
- Where
- Germany
- Volunteers
- 554 people
- Sponsor
- Bayer
Peripheral Arterial Disease
Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease
This study is a double-blind study to evaluate the efficacy and safety of NV1FGF, a pCOR plasmid constructed by inserting the gene coding for the FGF compared to placebo in patients with severe Peripheral Arterial Occlusive…
- Trial name
- TALISMAN 201 (NCT00368797)
- Testing
- XRP0038 (NV1FGF)
- Where
- 6 sites in Belgium, France and 4 more
- Volunteers
- 125 people
- Sponsor
- Sanofi
High Blood Pressure, Metabolic Syndrome
Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome
The purpose of this study was to determine the effects of Aliskiren on insulin resistance (IR) and endothelial dysfunction (ED) in patients with high blood pressure and metabolic syndrome.
- Conditions
- High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
- Trial name
- NCT00417170
- Testing
- Aliskiren, Amlodipine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age
This first open-label study in a pediatric population was designed to evaluate aliskiren safety and pharmacokinetics after single and multiple dosing in 6-17 year old children with hypertension.
- Trial name
- NCT00834041
- Testing
- Aliskiren 3.125 mini-tablets
- Where
- 5 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Novartis
Fabry Disease
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease
Primary Objective: To assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and exploratory efficacy of GZ/SAR402671 in enzyme replacement therapy treatment-naïve adult male participants diagnosed with Fabry disease.
- Trial name
- NCT02228460
- Testing
- GZ/SAR402671
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Genzyme, a Sanofi Company
Carotid Artery Disease
Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy (SAPPHIRE)
The primary objective of this study is to compare the safety and effectiveness of the Cordis Nitinol Carotid Stent and Delivery Systems (5.5 F and 7 F) with the ANGIOGUARD XP distal protective device to CEA in the treatment of…
- Trial name
- NCT00231270
- Testing
- Cordis Nitinol Stent, PRECISE tapered stent, ANGIOGUARD XP Emboli Capture Guidewire (ECGW)
- Volunteers
- 1,300 people
- Sponsor
- Cordis US Corp.
Relapsed/Refractory Multiple Myeloma
A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma
This study is a single-arm, open-label, multicenter, post-marketing, Phase IV, prospective, observational clinical trial to evaluate the efficacy and safety of the post-marketing product zevor-cel as treatment for subjects with…
- Trial name
- NCT06659770
- Testing
- Zevorcabtagene Autoleucel
- Volunteers
- 200 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Stroke
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
The present study is to be conducted based on the AIS patient data collected from CNSR I, II, and III. The primary objectives are: To investigate the temporal changes in the proportion of intravenous recombinant plasminogen…
- Trial name
- NCT04290494
- Testing
- IV rtPA (intravenous recombinant plasminogen activator)
- Where
- China
- Volunteers
- 42,188 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation, Stroke
Using Left Atrium Appendage Closure in NVAF Patients With High Risk of Ischemic Stroke
To evaluate the safety and efficacy of using Microport CardioAdvance Left Atrium Appendage Closure for preventing stroke in Non-valvular atrial fibrillation (NVAF) patients who have contraindications for long-term…
- Trial name
- SAFE-PROTECT (NCT04479722)
- Testing
- Left atrial appendage closure procedure
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.